HOXA9 and acute myeloid leukemia: HOXA9 is a transcription factor that can be used as a prognostic indicator for AML because its dysregulation is associated with AML progression (Deshpande and Zhu, 2023; Lai et al., 2020; Salik et al., 2020; Xiao et al., 2023), specifically by recruiting EZH2 to inhibit INK4A/B (cell cycle inhibitor) expression and subsequently affecting T-cell senescence (Collins and Hess, 2016a; b).